Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.64 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | OGFRL1 | Q5TC84 | 5/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411849 | 0.88 | OPRM1 (0.53) | OPRM1OPRL1MEN1KMT2AMAPT | |
| Citric Acid SCHEMBL16495856 | 0.87 | OPRM1 (0.50) | OPRM1OPRL1MEN1KMT2AMAPT | |
| SCHEMBL682596 | 0.78 | OPRM1 (0.64) | OPRM1OPRL1MEN1KMT2AMAPT | |
| SCHEMBL4114262 | 0.78 | OPRM1 (1.00) | OPRM1OPRL1OGFRL1OPRD1OPRK1 | |
| SCHEMBL11824291 | 0.74 | MEN1 (0.54) | OPRM1OPRL1MEN1KMT2AMAPT | |
| SCHEMBL10576386 | 0.73 | MEN1 (0.58) | OPRM1OPRL1MEN1KMT2AMAPT | |
| SCHEMBL30364176 | 0.72 | SIGMAR1 (0.77) | OPRM1OPRL1MEN1KMT2AGRIN2D | |
| SCHEMBL1702774 | 0.71 | CFTR (0.55) | OPRM1OPRL1MEN1KMT2AMAPT | |
| SCHEMBL1702808 | 0.71 | OPRM1 (0.68) | OPRM1OPRL1MEN1KMT2AMAPT | |
| SCHEMBL3408966 | 0.71 | OPRM1 (0.67) | OPRM1OPRL1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288430-B2 | Spiro(5.5)undecane derivatives | GRUNENTHAL GMBH (DE) | 2012-10-16 | — | — | US | claimed |
| EP-2257526-B1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-12-14 | — | — | EP | claimed |
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | claimed |
| US-8288430-B2 | Spiro(5.5)undecane derivatives | GRUNENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288430-B2 | Spiro(5.5)undecane derivatives | GRUNENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8288430-B2 | Spiro(5.5)undecane derivatives | GRUNENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2257526-B1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2257526-B1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-12-14 | — | — | EP | disclosed |
| WO-2009118169-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247505-A1 | SPIRO(5.5)UNDECANE DERIVATIVES | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885OPRL1 1/4885MEN1 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.